Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study.

IF 2.2 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2026-05-01 Epub Date: 2026-03-03 DOI:10.1080/07357907.2026.2633602

Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

{"title":"Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study.","authors":"Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai","doi":"10.1080/07357907.2026.2633602","DOIUrl":null,"url":null,"abstract":"We analyzed survival rates and prognostic factors for renal sarcoma using Japan's National Cancer Registry data. We conducted a retrospective cohort study of patients diagnosed with renal sarcoma (2016-2019). Prognostic factors were evaluated using Cox regression analyses. Among 235 patients, female sex (HR, 0.43; 95% CI, 0.23-0.83; p = 0.012), older age (≥60 years: HR, 5.87; p < 0.001), histologic subtype (angiosarcoma: HR, 12.65; p < 0.001), and distant disease (HR, 6.32; p < 0.001) were significant independent prognostic factors. Surgical resection (HR, 0.41; p = 0.004) and radiation therapy (HR, 0.39; p = 0.010) were associated with improved survival. Histologic subtype is the most critical prognostic factor for renal sarcoma in Japan's aging population, with dramatic survival differences: clear cell sarcoma (94.4% 3-year survival) versus angiosarcoma (19.0%). This heterogeneity mandates histology-specific treatment protocols rather than organ-based approaches, with particular relevance for aging societies in Asia.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"516-525"},"PeriodicalIF":2.2000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2026.2633602","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We analyzed survival rates and prognostic factors for renal sarcoma using Japan's National Cancer Registry data. We conducted a retrospective cohort study of patients diagnosed with renal sarcoma (2016-2019). Prognostic factors were evaluated using Cox regression analyses. Among 235 patients, female sex (HR, 0.43; 95% CI, 0.23-0.83; p = 0.012), older age (≥60 years: HR, 5.87; p < 0.001), histologic subtype (angiosarcoma: HR, 12.65; p < 0.001), and distant disease (HR, 6.32; p < 0.001) were significant independent prognostic factors. Surgical resection (HR, 0.41; p = 0.004) and radiation therapy (HR, 0.39; p = 0.010) were associated with improved survival. Histologic subtype is the most critical prognostic factor for renal sarcoma in Japan's aging population, with dramatic survival differences: clear cell sarcoma (94.4% 3-year survival) versus angiosarcoma (19.0%). This heterogeneity mandates histology-specific treatment protocols rather than organ-based approaches, with particular relevance for aging societies in Asia.

查看原文本刊更多论文

肾肉瘤的临床特征和预后因素：一项日本国家癌症登记研究。

我们使用日本国家癌症登记处的数据分析了肾肉瘤的生存率和预后因素。我们对诊断为肾肉瘤的患者（2016-2019）进行了回顾性队列研究。采用Cox回归分析评估预后因素。在235例患者中，女性（HR, 0.43; 95% CI, 0.23-0.83; p = 0.012）、年龄（≥60岁：HR， 5.87; p p p p = 0.004）和放疗（HR, 0.39; p = 0.010）与生存率提高相关。在日本老龄化人群中，组织学亚型是肾肉瘤最关键的预后因素，存在显著的生存差异：透明细胞肉瘤（3年生存率为94.4%）与血管肉瘤（19.0%）。这种异质性要求采用组织学特异性治疗方案，而不是基于器官的治疗方法，这与亚洲老龄化社会尤其相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.